SAB Biotherapeutics

SABSW42

Penny Stock

$0.07arrow_drop_up9.11%$0.00

Penny Stock

SABSW42

$0.07

arrow_drop_up9.11%$0.00

Penny Stock

Performance History

Key Stats
Open	$0.05
Prev. Close	$0.06
EPS	0.29
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$0.00

	LOW	HIGH
Day Range	0.05	0.06
52 Week Range	0.01	0.18

Ratios

Revenue	-





EPS	0.29

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About SAB Biotherapeutics (SABSW)

SAB Biotherapeutics, Inc. (SABSW) is a biotechnology company that specializes in the development of human antibody therapeutics. The company's focus is on utilizing its proprietary DiversitAb™ platform to produce fully human antibodies in a rapid and cost-effective manner. These antibodies have the potential to treat a wide range of diseases, including infectious diseases, autoimmune disorders, and cancer. SABSW's innovative approach harnesses the power of transchromosomic cattle, which have been genetically engineered to produce human antibodies in their milk. This unique platform allows for the production of large quantities of antibodies with high specificity and potency.

One of the key advantages of SABSW's approach is its ability to rapidly respond to emerging infectious diseases. Traditional vaccine development can take years, but SABSW's platform enables the production of fully human antibodies within a matter of months. This speed and scalability provide a significant advantage in addressing global health threats such as pandemics. SABSW has demonstrated the effectiveness of its approach in preclinical studies, where its human antibody therapeutics have shown strong efficacy against multiple pathogens, including influenza, Ebola, Zika, and COVID-19.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Eddie Joe Sullivan Ph.D.
Headquarters: Sioux Falls
Employees: 56
Exchange: NASDAQ

Keep an eye on SAB Biotherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is SAB Biotherapeutics's (SABSW) price per share?

The current price per share for SAB Biotherapeutics (SABSW) is $0.07. The stock has seen a price change of $0.01 recently, indicating a 9.12% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for SAB Biotherapeutics (SABSW)?

For SAB Biotherapeutics (SABSW), the 52-week high is $0.18, which is 146.58% from the current price. The 52-week low is $0.02, the current price is 356.25% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is SAB Biotherapeutics (SABSW) a growth stock?

SAB Biotherapeutics (SABSW) has shown an average price growth of -6.03% over the past three years. It has received a score of -8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying SAB Biotherapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is SAB Biotherapeutics (SABSW) stock price performance year to date (YTD)?

As of the latest data, SAB Biotherapeutics (SABSW) has a year-to-date price change of 239.53%. Over the past month, the stock has experienced a price change of 34.19%. Over the last three months, the change has been 143.33%. Over the past six months, the figure is 92.11%.

help

Is SAB Biotherapeutics (SABSW) a profitable company?

SAB Biotherapeutics (SABSW) has a net income of -$42.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.42K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$38.08M. Furthermore, the EBITDA is -$46.91M.

help

What is the market capitalization of SAB Biotherapeutics (SABSW)?

SAB Biotherapeutics (SABSW) has a market capitalization of $0. The average daily trading volume is 0.06, indicating the stock's liquidity and investor engagement.